摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-(Trifluoromethyl)-2-[4-(trifluoromethyl)piperidin-1-yl]aniline | 175277-70-0

中文名称
——
中文别名
——
英文名称
5-(Trifluoromethyl)-2-[4-(trifluoromethyl)piperidin-1-yl]aniline
英文别名
——
5-(Trifluoromethyl)-2-[4-(trifluoromethyl)piperidin-1-yl]aniline化学式
CAS
175277-70-0
化学式
C13H14F6N2
mdl
——
分子量
312.25
InChiKey
QTBDURJFYHOORY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.1
  • 重原子数:
    21
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.54
  • 拓扑面积:
    29.3
  • 氢给体数:
    1
  • 氢受体数:
    8

文献信息

  • Nf-kb activation inhibitors
    申请人:Muto Susumu
    公开号:US20060089395A1
    公开(公告)日:2006-04-27
    A medicament having inhibitory activity against NF-κB activation which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein A represents hydrogen atom or acetyl group, E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is circle around (1)} a fused polycyclic heteroaryl group wherein the ring which binds directly to —CONH— group in the formula (I) is a benzene ring, circle around (2)} unsubstituted thiazol-2-yl group, or circle around (3)} unsubstituted benzothiazol-2-yl group is excluded, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —CONH-E wherein E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —CONH-E wherein E has the same meaning as that defined above.
    一种药物具有抑制NF-κB活化作用,其包括以下通式(I)所表示的化合物或其药学上可接受的盐、水合物和溶剂化物作为活性成分,其中A代表氢原子或乙酰基,E代表2,5-二取代或3,5-二取代苯基或单环或融合的多环杂环芳基,其可以被取代,但在所述杂环芳基是圆圈(1)}在公式(I)中直接结合—CONH—基团的环为苯环的融合多环杂环芳基,圆圈(2)}未取代的噻唑-2-基团,或者圆圈(3)}未取代的苯并噻唑-2-基团时,不包括该化合物,环Z代表一个芳香烃,除了由公式—O-A所表示的基团外,它也可以有一个或多个取代基,其中A具有与上述定义相同的含义,公式—CONH-E所表示的基团E具有与上述定义相同的含义。
  • Inhibitors against the activation of ap-1 and nfat
    申请人:Muto Susumu
    公开号:US20060100257A1
    公开(公告)日:2006-05-11
    A medicament inhibiting the activation of AP-1 which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.
    一种药物,抑制AP-1的激活,其活性成分为以下通式(I)所表示的化合物或其药学上可接受的盐、水合物或溶剂化物中所选的一种,其中X代表连接基,其主链中的原子数为2至5(该连接基可以被取代),A代表氢原子或乙酰基,E代表芳基或取代的杂芳基,环Z代表芳烃,除了由式—O-A所表示的基团外,可能还有一个或多个取代基,其中A具有上述定义的相同含义,由式—X-E所表示的基团中,X和E的每一个具有上述定义的相同含义,或者是一个杂芳烃,可能还有一个或多个取代基,其中A具有上述定义的相同含义,由式—X-E所表示的基团中,X和E的每一个具有上述定义的相同含义。
  • Medicament for treatment of diabetes
    申请人:Muto Susumu
    公开号:US20060111409A1
    公开(公告)日:2006-05-25
    A medicament for preventive and/or therapeutic treatment of diabetes or complications of diabetes which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O— A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.
    一种用于预防和/或治疗糖尿病或糖尿病并发症的药物,其活性成分为以下通式(I)所表示的化合物或其药学上可接受的盐、水合物或溶剂化物之一: 其中,X代表主链中原子数为2到5的连接基(该连接基可以被取代),A代表氢原子或乙酰基,E代表可以被取代的芳基或杂环芳基,环Z代表可以具有一个或多个取代基的芳基,除了由公式—O—A所表示的基团外,该芳基可以具有公式—X-E所表示的基团,其中每个X和E的含义与上述定义相同,或者可以具有一个或多个取代基的杂环芳基,除了由公式—O—A所表示的基团外,该杂环芳基可以具有公式—X-E所表示的基团,其中每个X和E的含义与上述定义相同。
  • Antiallergic
    申请人:Muto Susumu
    公开号:US20060122243A1
    公开(公告)日:2006-06-08
    A medicament for the preventive and/or therapeutic treatment of allergic diseases and/or endometriosis and/or hysteromyoma which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.
    一种用于预防和/或治疗过敏性疾病和/或子宫内膜异位症和/或子宫肌瘤的药物,其包括以下通式(I)所表示的化合物或其药学上可接受的盐、水合物和溶剂化物作为活性成分,其中X代表主链中原子数为2到5的连接基(该连接基可以被取代),A代表氢原子或乙酰基,E代表可以被取代的芳基或杂环芳基,环Z代表可以具有一个或多个取代基的芳烃,除了由公式-O-A所表示的基团外,该芳烃还可以具有公式—X-E所表示的基团,其中每个X和E具有上述定义的相同含义,或者该环可以具有一个或多个取代基,除了由公式—O-A所表示的基团外,该环还可以具有公式—X-E所表示的基团,其中A具有上述定义的相同含义,X和E分别具有上述定义的相同含义。
  • Medicament for treatment of cancer
    申请人:Muto Susumu
    公开号:US20060014811A1
    公开(公告)日:2006-01-19
    A medicament for the prevention and/or treatment of cancers and the like which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein A represents hydrogen atom or acetyl group, E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is circle around (1)} a fused polycyclic heteroaryl group wherein the ring which binds directly to —CONH— group in the formula (I) is a benzene ring, circle around (2)} unsubstituted thiazol-2-yl group, or circle around (3)} unsubstituted benzothiazol-2-yl group is excluded, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —CONH-E wherein E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —CONH-E wherein E has the same meaning as that defined above.
    预防和/或治疗癌症及类似疾病的药物,其活性成分为以下通式(I)所代表的化合物中所选的一种或其药学上可接受的盐,以及其水合物和溶剂化物:其中A代表氢原子或乙酰基,E代表2,5-二取代或3,5-二取代苯基,或单环或融合的多环杂环芳基,可以被取代,但其中异杂环基团为circle around (1)}在公式(I)中直接结合—CONH—基团的环为苯环的融合多环杂环芳基,circle around (2)}未取代的噻唑-2-基团,或circle around (3)}未取代的苯并噻唑-2-基团被排除,环Z代表一个芳烃,除了由公式—O-A所代表的基团和由公式—CONH-E所代表的基团以外,它可以有一个或多个取代基,其中A具有上述定义的相同含义,E具有上述定义的相同含义,或者它可以是一个具有上述定义的相同含义的杂芳烃,它可以有一个或多个取代基。
查看更多